中华中医药学刊

蟾毒灵的抗癌作用机制及组学研究进展

PDF下载

王潇凡 ¹^,² , 张墨涵 ¹^,² , 林事成 ¹^,² , 张语馨 ¹^,² , 李依聪 ¹^,² , 胡凯文 ¹^,² , 李泉旺 ¹^,²

中华中医药学刊 | 国家项目点击 2026,44(5): 125-131

收起

中华中医药学刊 |国家项目点击 2026 , 44 (5) : 125 -131

蟾毒灵的抗癌作用机制及组学研究进展

全屏

王潇凡¹^,², 张墨涵¹^,², 林事成¹^,², 张语馨¹^,², 李依聪¹^,², 胡凯文¹^,², 李泉旺¹^,²

作者信息

^1．北京中医药大学，北京 100070

^2．北京中医药大学东方医院，北京 100070

通讯作者:

李泉旺（1970-），男，河北保定人，主任医师、教授，博士研究生导师，硕士，研究方向：中西医结合防治肿瘤。E-mail：quanwangli@126.com。

作者简介:

王潇凡（1996-），女，河南灵宝人，博士在读，研究方向：中西医结合防治肿瘤。

Research Progress of Anticancer Mechanism and Omics of Bufalin

Xiaofan WANG¹^,², Mohan ZHANG¹^,², Shicheng LIN¹^,², Yuxin ZHANG¹^,², Yicong LI¹^,², Kaiwen HU¹^,², Quanwang LI¹^,²

Affiliations

^1. Beijing University of Chinese Medicine, Beijing 100070, China

^2. Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100070, China

出版时间: 2026-05-10 doi: 10.13193/j.issn.1673-7717.2026.05.024

文章导航

摘要

收起

癌症仍是全球主要公共卫生问题，因其难治性及高致死率成为严重威胁人类健康的疾病。中药及其有效成分在治疗恶性肿瘤方面已积累大量理论基础及实践经验。蟾毒灵是从中华大蟾蜍或黑眶蟾蜍皮肤中提取分离出的一种强心苷类化合物。现代研究证明，蟾毒灵对肝癌、肺癌、结直肠癌、乳腺癌等多种肿瘤具有广谱抗癌药理活性。其抗癌机制主要包括抑制肿瘤细胞增殖、侵袭与转移、血管生成、癌细胞干性，诱导凋亡和自噬，逆转耐药、增强化疗敏感性及免疫功能。组学技术的应用与发展为研究蟾毒灵抗肿瘤机制提供新的视野和策略。因此，本综述纳入最新研究文献，更新了蟾毒灵抗癌作用机制，并首次聚焦基因组学、转录组学、蛋白质组学及代谢组学技术在蟾毒灵调控恶性肿瘤发生发展中的作用机制，围绕相关机制及组学技术开展的中医药实验成果进行总结，旨在为后续更深入的机制研究及多组学的应用提供参考和借鉴。

关键词

蟾毒灵 / 抗癌 / 作用机制 / 组学技术 / 研究进展

Abstract

收起

Cancer is still a major public health problem in the world, and it has become a serious threat to human health due to its refractory and high fatality rate. Traditional Chinese Medicine and its active ingredients have accumulated a lot of theoretical basis and practical experience in the treatment of malignant tumors. Bufalin is a cardiac glycoside compound isolated from the skin of Zhonghua Dachanchu (Bufo gargarizans) or Heikuang Chanchu (Bufo melanostictus) . Modern studies have proved that bufalin has broad-spectrum anti-cancer pharmacological activity against liver cancer, lung cancer, colorectal cancer, breast cancer and other tumors. Its anti-cancer mechanism mainly includes inhibition of tumor cell proliferation, invasion and metastasis, angiogenesis, cancer stem cancer, induction of apoptosis and autophagy, reversal of drug resistance, enhancement of chemotherapy sensitivity and immune function. The application and development of omics technology provide a new vision and strategy for studying the anti-tumor mechanism of bufalin. Therefore, this review included the latest research literature, updated the anti-cancer mechanism of bufalin, focused on the mechanism of genomics, transcriptomics, proteomics and metabolomics technology in the regulation of bufalin in the development of malignant tumors for the first time, and summarized the anti-cancer molecular mechanism of bufalin and the experimental results of traditional Chinese medicine based on related mechanisms and omics technology. The aim was to provide reference for further mechanism research and application of multiomics.

Key words

bufalin / anti-cancer / mechanism of action / omics technology / research progress

引用本文

王潇凡, 张墨涵, 林事成, 张语馨, 李依聪, 胡凯文, 李泉旺. 蟾毒灵的抗癌作用机制及组学研究进展. 中华中医药学刊, 2026 , 44 (5) : 125 -131 . DOI: 10.13193/j.issn.1673-7717.2026.05.024

Xiaofan WANG, Mohan ZHANG, Shicheng LIN, Yuxin ZHANG, Yicong LI, Kaiwen HU, Quanwang LI. Research Progress of Anticancer Mechanism and Omics of Bufalin[J]. Chinese Archives of Traditional Chinese Medicine, 2026 , 44 (5) : 125 -131 . DOI: 10.13193/j.issn.1673-7717.2026.05.024

基金

收起

国家重点研发计划项目(2018YFC1705100)
国家自然科学基金青年科学基金项目(82104957)
中央高校基本科研业务费专项资金资助北京中医药大学重点攻关项目(2020-JYB-ZDGG-127)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

［1］

SIEGEL R L, GIAQUINTO A N, JEMAL A. Cancer statistics, 2024［J］. CA Cancer J Clin, 2024, 74 (1) : 12-49.

［2］

ZHANG C Y, XU C, GAO X Y, et al. Platinum-based drugs for cancer therapy and anti-tumor strategies［J］. Theranostics, 2022, 12 (5) : 2115-2132.

［3］

LUO H, VONG C T, CHEN H B, et al. Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine［J］. Chin Med, 2019, 14 (1) : 48.

［4］

赵军，王小强，谢兴文，等.中药单体及有效成分抗肿瘤作用机制的研究进展［J］.中华中医药杂志，2024，39（6）：3002-3009.

［5］

TANG D H, FENG Y J, LU J H, et al. Global trends in bufalin application research for cancer from 2003 to 2022: a bibliometric and visualised analysis［J］. Heliyon, 2024, 10 (2) : e24395.

［6］

SOUMOY L, GHANEMG E, SAUSSEZ S, et al. Bufalin for an innovative therapeutic approach against cancer［J］. Pharmacol Res, 2022, 184: 106442.

［7］

YE Q M, ZHOU X, REN H, et al. An overview of the past decade of bufalin in the treatment of refractory and drug-resistant cancers: current status, challenges, and future perspectives［J］. Front Pharmacol, 2023, 14: 1274336.

［8］

邱文艳，陈思雅，颜红，等．蟾毒灵抗肝肿瘤活性及靶向载药系统研究进展［J］．湖南中医杂志，2023，39（5）：189-193.

［9］

BAYSOY A, BAI Z L, SATIJA R, et al. The technological landscape and applications of single-cell multi-omics［J］. Nat Rev Mol Cell Biol, 2023, 24 (10) : 695-713.

［10］

林浩，代伟宏，刘昌江，等.中药单体活性成分抗结直肠癌的研究进展［J］．天然产物研究与开发，2023，35（9）：1637-1649.

［11］

DHANASEKARAN R, DEUTZMANN A, MAHAUAD-FERNANDEZ W D, et al. The MYC oncogene—the grand orchestrator of cancer growth and immune evasion［J］. Nat Rev Clin Oncol, 2022, 19 (1) : 23-36.

［12］

LIU X, ZHOU Y Y, PENG J M, et al. Silencing c-myc enhances the antitumor activity of bufalin by suppressing the HIF-1 α/SDF-1/CXCR4 pathway in pancreatic cancer cells［J］. Front Pharmacol, 2020, 11: 495.

［13］

SONG J C, ZOU D, ZHAO X X, et al. Bufalin inhibits human diffuse large B-cell lymphoma tumorigenesis by inducing cell death through the Ca²⁺/NFATC1/cMYC pathway［J］. Carcinogenesis, 2021, 42 (2) : 303-314.

［14］

KIMN Y, SUH Y A, KIMS, et al. Bufalin down-regulates Axl expression to inhibit cell proliferation and induce apoptosis in non-small-cell lung cancer cells［J］. Biosci Rep, 2020, 40 (4) : BSR20193959.

［15］

XIE J L, LIN W F, HUANG L L, et al. Bufalin suppresses the proliferation and metastasis of renal cell carcinoma by inhibiting the PI3K/Akt/mTOR signaling pathway［J］. Oncol Lett, 2018, 16 (3) : 3867-3873.

［16］

HSU C M, TSAI Y, WAN L, et al. Bufalin induces G2/M phase arrest and triggers autophagy via the TNF, JNK, BECN-1 and ATG8 pathway in human hepatoma cells［J］. Int J Oncol, 2013, 43 (1) : 338-348.

［17］

CHEN F, ZHU L, HU J Y, et al. Bufalin attenuates triple-negative breast cancer cell stemness by inhibiting the expression of SOX2/OCT4［J］. Oncol Lett, 2020, 20 (5) : 171.

［18］

DOU L, ZOU D, SONG F R, et al. Bufalin suppresses ovarian cancer cell proliferation via EGFR pathway［J］. Chin Med J, 2021, 135 (4) : 456-461.

［19］

LI H R, HU S, PANG Y Y, et al. Bufalin inhibits glycolysis-induced cell growth and proliferation through the suppression of Integrin β2/FAK signaling pathway in ovarian cancer［J］. Am J Cancer Res, 2018, 8 (7) : 1288-1296.

［20］

CARNEIRO B A, EL-DEIRY W S. Targeting apoptosis in cancer therapy［J］. Nat Rev Clin Oncol, 2020, 17 (7) : 395-417.

［21］

KALONI D, DIEPSTRATEN S T, STRASSER A, et al. BCL-2 protein family: attractive targets for cancer therapy［J］. Apoptosis, 2023, 28 (1-2) : 20-38.

［22］

QIAN L Q, SU H Y, WANG G, et al. Anti-tumor activity of bufalin by inhibiting c-MET mediated MEK/ERK and PI3K/AKT signaling pathways in gallbladder cancer［J］. J Cancer, 2020, 11 (11) : 3114-3123.

［23］

LEE C H, SHIH Y L, LEE MH, et al. Bufalin induces apoptosis of human osteosarcoma U-2 OS cells through endoplasmic reticulum stress, caspase-and mitochondria-dependent signaling pathways［J］. Molecules, 2017, 22 (3) : 437.

［24］

CHOU H Y, CHUEH F S, MA Y S, et al. Bufalin induced apoptosis in SCC-4 human tongue cancer cells by decreasing Bcl-2 and increasing Bax expression via the mitochondria-dependent pathway［J］. Mol Med Rep, 2017, 16 (6) : 7959-7966.

［25］

DAI X Y, ZHOU B F, XIE Y Y, et al. Bufalin and 5-fluorouracil synergistically induce apoptosis in colorectal cancer cells［J］. Oncol Lett, 2018, 15 (5) : 8019-8026.

［26］

KUO J Y, LIAO C L, MA Y S, et al. Combination treatment of sorafenib and bufalin induces apoptosis in NCI-H292 human lung cancer cells in vitro［J］. In Vivo, 2022, 36 (2) : 582-595.

［27］

GU R Z, ZHANG Q C. Effects of low-dose bufalin combined with hydroxycamptothecin on human castration-resistant prostate cancer xenografts in nude mice［J］. Exp Ther Med, 2021, 22 (3) : 1015.

［28］

LI T X, ZHANG Y T, LI H Y, et al. Bufalin CaCO (3) nanoparticles triggered pyroptosis through calcium overload via Na⁺/Ca (2+) exchanger reverse for cancer immunotherapy［J］. Nano Lett, 2024, 24 (40) : 12691-12700.

［29］

SOUMOY L, GENBAUFFE A, MOUCHART L, et al. ATP1 A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy［J］. Cancer Cell Int, 2024, 24 (1) : 8.

［30］

LI Y, ZHANG Y, WANG X F, et al. Bufalin induces mitochondrial dysfunction and promotes apoptosis of glioma cells by regulating Annexin A2 and DRP1 protein expression［J］. Cancer Cell Int, 2021, 21 (1) : 424.

［31］

LINGHU H R, LUO H, GANG L. Bufalin induces glioma cell death by apoptosis or necroptosis［J］. Onco Targets Ther, 2020, 13: 4767-4778.

［32］

ZHENG Y D, HE Z, SU Z C, et al. Bufalin induces apoptosis and autophagy via the Ca²⁺/CaMKKβ/AMPK/Beclin1 signaling pathway in osteosarcoma cells［J］. Cell Biol Int, 2023, 47 (8) : 1344-1353.

［33］

SHENG X, ZHU P F, QIN J M, et al. The biological role of autophagy in regulating and controlling the proliferation of liver cancer cells induced by bufalin［J］. Oncol Rep, 2018, 39 (6) : 2931-2941.

［34］

PAN Z, XIE Y P, BAI J, et al. Bufalin suppresses colorectal cancer cell growth through promoting autophagy in vivo and in vitro［J］. RSC Adv, 2018, 8 (68) : 38910-38918.

［35］

WU S Q, WU X M, WANG Q, et al. Bufalin induces ferroptosis by modulating the 2, 4-dienoyl-CoA reductase (DECR1) -SLC7A11 axis in breast cancer［J］. Phytomedicine, 2024, 135: 156130.

［36］

SHENG X, ZHU P F, ZHAO Y, et al. Effect of PI3K/AKT/mTOR signaling pathway on regulating and controlling the anti-invasion and metastasis of hepatoma cells by bufalin［J］. Recent Pat Anticancer Drug Discov, 2021, 16 (1) : 54-65.

［37］

QI H Y, QU X J, LIU J, et al. Bufalin induces protective autophagy by Cbl-b regulating mTOR and ERK signaling pathways in gastric cancer cells［J］. Cell Biol Int, 2019, 43 (1) : 33-43.

［38］

FAN Y B, ZHANG W, IQBAL Z, et al. Rod-shaped mesoporous silica nanoparticles reduce bufalin cardiotoxicity and inhibit colon cancer by blocking lipophagy［J］. Lipids Health Dis, 2024, 23 (1) : 318.

［39］

MHAIDLY N, BARAKE N, TRELCAT A, et al. Bufalin suppresses head and neck cancer development by modulating immune responses and targeting the β-catenin signaling pathway［J］. Cancers, 2024, 16 (15) : 2739.

［40］

YU Z, LI Y Y, LI Y, et al. Bufalin stimulates antitumor immune response by driving tumor-infiltrating macrophage toward M1 phenotype in hepatocellular carcinoma［J］. J Immunother Cancer, 2022, 10 (5) : e004297.

［41］

ZHANG X M, LU X N, SHI J, et al. Bufalin suppresses hepatocellular carcinogenesis by targeting M2 macrophage-governed Wnt1/β-catenin signaling［J］. Phytomedicine, 2024, 126: 155395.

［42］

SHIH Y L, CHOU J S, CHEN Y L, et al. Bufalin enhances immune responses in leukemic mice through enhancing phagocytosis of macrophage in vivo［J］. In Vivo, 2018, 32 (5) : 1129-1136.

［43］

FU R, YU F J, WU W Q, et al. Bufalin enhances the killing efficacy of NK cells against hepatocellular carcinoma by inhibiting MICA shedding［J］. Int Immunopharmacol, 2021, 101 (Pt B) : 108195.

［44］

WANG H J, CHEN J B, LI S, et al. Bufalin reverses cancer-associated fibroblast-mediated colorectal cancer metastasis by inhibiting the STAT3 signaling pathway［J］. Apoptosis, 2023, 28 (3-4) : 594-606.

［45］

WANG H Y, ZHANG C Y, CHI H Y, et al. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling［J］. Int J Oncol, 2018, 52 (6) : 2051-2060.

［46］

WANG H Y, ZHANG C Y, NING Z Y, et al. Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling［J］. Int J Oncol, 2016, 48 (3) : 1229-1241.

［47］

YUAN Z T, LIU C L, SUN Y J, et al. Bufalin exacerbates Photodynamic therapy of colorectal cancer by targeting SRC-3/HIF-1 α pathway［J］. Int J Pharm, 2022, 624: 122018.

［48］

ZOU D, SONG J C, DENG MM, et al. Bufalin inhibits peritoneal dissemination of gastric cancer through endothelial nitric oxide synthase-mitogen-activated protein kinases signaling pathway［J］. FASEB J, 2021, 35 (5) : e21601.

［49］

TONG Z W, ZHANG Y, GUO P, et al. Steroid receptor coactivator 1 promotes human hepatocellular carcinoma invasiveness through enhancing MMP-9［J］. J Cell Mol Med, 2024, 28 (7) : e18171.

［50］

HONG S H, KIM G Y, CHANG Y C, et al. Bufalin prevents the migration and invasion of T24 bladder carcinoma cells through the inactivation of matrix metalloproteinases and modulation of tight junctions［J］. Int J Oncol, 2013, 42 (1) : 277-286.

［51］

ZHAO L, LIU S Z, CHE X F, et al. Bufalin inhibits TGF-β-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGF-βreceptors［J］. Int J Mol Med, 2015, 36 (3) : 645-652.

［52］

GAO Y, SHELLING A N, NOLAN E, et al. Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells［J］. J Liposome Res, 2024, 34 (3) : 489-506.

［53］

ZHANG D, JIA T T, CHEN X X, et al. Bufalin reverses ABCB1-mediated resistance to docetaxel in breast cancer［J］. Heliyon, 2023, 9 (3) : e13840.

［54］

LIU X D, SONG C Y, KONG C C, et al. Bufalin induces programmed necroptosis in triple-negative breast cancer drug-resistant cell lines through RIP1/ROS-mediated pathway［J］. Chin J Integr Med, 2022, 28 (10) : 900-908.

［55］

CHEN J B, WANG H J, JIA L L, et al. Bufalin targets the SRC-3/MIF pathway in chemoresistant cells to regulate M2 macrophage polarization in colorectal cancer［J］. Cancer Lett, 2021, 513: 63-74.

［56］

CAO F, GONG Y B, KANG X H, et al. Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer［J］. Toxicol Appl Pharmacol, 2019, 379: 114662.

［57］

WANG Z J, LIU F, HUANG C, et al. Bufalin inhibits epithelial-mesenchymal transition and increases radiosensitivity of non-small cell lung cancer via inhibition of the Src signaling［J］. J Thorac Dis, 2023, 15 (1) : 123-134.

［58］

ZHANG W, FAN Y B, ZHANG J Z, et al. Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer［J］. Drug Resist Updat, 2023, 71: 101005.

［59］

张文静，赵可旭，张可越，等．肿瘤干细胞生物学特性及其干性维持机制的研究进展［J］．生物工程学报，2024，40（2）：391-418.

［60］

刘晶晶，董君君，张蝶，等．蟾毒灵抑制低氧条件下乳腺癌细胞干性机制研究［J］.中国医院药学杂志，2023，43（10）：1071-1077.

［61］

DING L, YANG Y N, LU Q, et al. Bufalin inhibits tumorigenesis, stemness, and epithelial-mesenchymal transition in colorectal cancer through a C-kit/slug signaling axis［J］. Int J Mol Sci, 2022, 23 (21) : 13354.

［62］

ZHAN Y P, QIU Y Y, WANG H J, et al. Bufalin reverses multidrug resistance by regulating stemness through the CD133/nuclear factor-κB/MDR1 pathway in colorectal cancer［J］. Cancer Sci, 2020, 111 (5) : 1619-1630.

［63］

MADDEN E B, HINDORFF L A, BONHAMV L, et al. Advancing genomics to improve health equity［J］. Nat Genet, 2024, 56 (5) : 752-757.

［64］

林家茂，张晨月，部帅，等．功能基因组学方法筛选蟾毒灵抗肝癌细胞的潜在凋亡靶点［J］．世界中医药，2022，17（8）：1047-1051.

［65］

CHEN A L, YU J, ZHANG L, et al. Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells［J］. Biotechnol Lett, 2009, 31 (4) : 487-494.

［66］

LIAN X Y, WANG H, WEI X C, et al. BMI-1 is important in bufalin-induced apoptosis of K562 cells［J］. Mol Med Rep, 2014, 9 (4) : 1209-1217.

［67］

WANG L P, ZHAO Y N, SUN X, et al. Effects of bufalin on up-regulating methylation of Wilm’s tumor 1 gene in human erythroid leukemic cells［J］. Chin J Integr Med, 2017, 23 (4) : 288-294.

［68］

WANG Q, LI C, ZHU Z T, et al. miR-155-5p antagonizes the apoptotic effect of bufalin in triple-negative breast cancer cells［J］. Anticancer Drugs, 2016, 27 (1) : 9-16.

［69］

TSIMBERIDOU A M, FOUNTZILAS E, BLERIS L, et al. Transcriptomics and solid tumors: The next frontier in precision cancer medicine［J］. Semin Cancer Biol, 2022, 84: 50-59.

［70］

HE B X, ZHAO Z Y, CAI Q D, et al. miRNA-based biomarkers, therapies, and resistance in Cancer［J］. Int J Biol Sci, 2020, 16 (14) : 2628-2647.

［71］

ZHANG J J, SHA J J, ZHOU Y, et al. Bufalin inhibits proliferation and induces apoptosis in osteosarcoma cells by downregulating microRNA-221［J］. Evid Based Complement Alternat Med, 2016, 2016: 7319464.

［72］

ZHAO H Y, ZHAO D L, TAN G, et al. Bufalin promotes apoptosis of gastric cancer by down-regulation of miR-298 targeting bax［J］. Int J Clin Exp Med, 2015, 8 (3) : 3420-3428.

［73］

SUN X C, CUI M H, TONG L L, et al. Upregulation of microRNA-3129 suppresses epithelial ovarian cancer through CD44［J］. Cancer Gene Ther, 2018, 25 (11-12) : 317-325.

［74］

CHANG Y W, ZHAO Y F, GU W, et al. Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through mir-148a［J］. Cell Physiol Biochem, 2015, 36 (3) : 1186-1196.

［75］

王海永，张晨月，李佳，等．蟾毒灵抑制肝癌干细胞lncRNAs分子筛选研究［J］.中国中医药信息杂志，2021，28（12）：41-44.

［76］

GONG MM, WANG X, MU L, et al. Steroid receptor coactivator-1 enhances the stemness of glioblastoma by activating long noncoding RNA XIST/miR-152/KLF4 pathway［J］. Cancer Sci, 2021, 112 (2) : 604-618.

［77］

JIN J, YAO Z P, QIN H J, et al. Bufalin inhibits the malignant development of non-small cell lung cancer by mediating the circ_0046264/miR-522-3p axis［J］. Biotechnol Lett, 2021, 43 (6) : 1229-1240.

［78］

MANI D R, KRUG K, ZHANG B, et al. Cancer proteogenomics: current impact and future prospects［J］. Nat Rev Cancer, 2022, 22 (5) : 298-313.

［79］

PAN L J, NIE L T, YAO S, et al. Bufalin exerts antitumor effects in neuroblastoma via the induction of reactive oxygen species-mediated apoptosis by targeting the electron transport chain［J］. Int J Mol Med, 2020, 46 (6) : 2137-2149.

［80］

CHEN G, ZHANG H H, SUN H X, et al. Bufalin targeting BFAR inhibits the occurrence and metastasis of gastric cancer through PI3K/AKT/mTOR signal pathway［J］. Apoptosis, 2023, 28 (9-10) : 1390-1405.

［81］

ZHANG D M, FENG L X, LIU M, et al. Possible target-related proteins and signal network of bufalin in A549 cells suggested by both iTRAQ-based and label-free proteomic analysis［J］. Proteomics, 2016, 16 (6) : 935-945.

［82］

PAN S N, WANG Y H, FENG L X, et al. Study on proteomics of Hela cell apoptosis in bufalin-induced human cervical carcinoma［J］. Zhongguo Zhongyao Zazhi, 2012, 37 (13) : 1998-2004.

［83］

XIE X B, YIN J Q, WEN L L, et al. Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research［J］. PLoS One, 2012, 7 (10) : e47375.

［84］

谢显彪，温丽丽，尹军强，等．蟾毒灵诱导骨肉瘤细胞株凋亡的蛋白质组学研究［J］.中国中药杂志，2014，39（14）：2739-2743.

［85］

SCHMIDT D R, PATEL R, KIRSCH D G, et al. Metabolomics in cancer research and emerging applications in clinical oncology［J］. CA Cancer J Clin, 2021, 71 (4) : 333-358.

［86］

SHI S L, ZHAO S H, TIAN X C, et al. Molecular and metabolic mechanisms of bufalin against lung adenocarcinoma: New and comprehensive evidences from network pharmacology, metabolomics and molecular biology experiment［J］. Comput Biol Med, 2023, 157: 106777.

［87］

HUANG C J, ZHANG C Y, ZHAO Y K, et al. Bufalin inhibits tumorigenesis and SREBP-1-mediated lipogenesis in hepatocellular carcinoma via modulating the ATP1 A1/CA2 axis［J］. Am J Chin Med, 2023, 51 (2) : 461-485.

［88］

HAN X L, GROSS R W. The foundations and development of lipidomics［J］. J Lipid Res, 2022, 63 (2) : 100164.

［89］

ZHANG J H, HONG Y J, XIE P S, et al. Spatial lipidomics reveals anticancer mechanisms of bufalin in combination with cinobufagin in tumor-bearing mice［J］. Front Pharmacol, 2021, 11: 593815.

［90］

ZHANG J H, HONG Y J, JIANG L L, et al. Global metabolomic and lipidomic analysis reveal the synergistic effect of bufalin in combination with cinobufagin against HepG2 cells［J］. J Proteome Res, 2020, 19 (2) : 873-883.

［91］

AHMAD FAROOQI A, RAKHMETOVA V S, KAPANOVA G, et al. Bufalin-mediated regulation of cell signaling pathways in different cancers: spotlight on JAK/STAT, Wnt/β-catenin, mTOR, TRAIL/TRAIL-R, and non-coding RNAs［J］. Molecules, 2023, 28 (5) : 2231.

［92］

HE X J, LIU X W, ZUO F L, et al. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine［J］. Semin Cancer Biol, 2023, 88: 187-200.

2026年第44卷第5期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.13193/j.issn.1673-7717.2026.05.024

首发时间：2026-10-14
出版时间：2026-05-10

补充材料

相关文章

文章信息

作者

出版历史

基金

国家重点研发计划项目(2018YFC1705100)

国家自然科学基金青年科学基金项目(82104957)

中央高校基本科研业务费专项资金资助北京中医药大学重点攻关项目(2020-JYB-ZDGG-127)

作者信息

^1．北京中医药大学，北京 100070

^2．北京中医药大学东方医院，北京 100070

通讯作者:

李泉旺（1970-），男，河北保定人，主任医师、教授，博士研究生导师，硕士，研究方向：中西医结合防治肿瘤。E-mail：quanwangli@126.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zhzyyxk/CN/10.13193/j.issn.1673-7717.2026.05.024

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT